vs
SUPERIOR GROUP OF COMPANIES, INC.（SGC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
SUPERIOR GROUP OF COMPANIES, INC.的季度营收约是再鼎医药的1.2倍（$146.6M vs $127.1M），再鼎医药同比增速更快（17.1% vs 0.8%），SUPERIOR GROUP OF COMPANIES, INC.自由现金流更多（$17.9M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 2.7%）
舒必利尔集团（Superior Coach）曾是美国汽车工业的车身制造商，其前身加尔福德卡车公司成立于1909年。该企业最为人熟知的业务是打造灵车等专业车辆车身以及校车车身。受1970年代末两大业务板块的严重衰退影响，公司于1980年被母公司清算，1925年至1980年间，企业总部设于俄亥俄州利马市。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
SGC vs ZLAB — 直观对比
营收规模更大
SGC
是对方的1.2倍
$127.1M
营收增速更快
ZLAB
高出16.3%
0.8%
自由现金流更多
SGC
多$44.6M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
2.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $146.6M | $127.1M |
| 净利润 | $3.5M | — |
| 毛利率 | 36.9% | 51.0% |
| 营业利润率 | 2.8% | -54.6% |
| 净利率 | 2.4% | — |
| 营收同比 | 0.8% | 17.1% |
| 净利润同比 | 65.8% | — |
| 每股收益（稀释后） | $0.23 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SGCZLAB
| Q4 25 | $146.6M | $127.1M | ||
| Q3 25 | $138.5M | $115.4M | ||
| Q2 25 | $144.0M | $109.1M | ||
| Q1 25 | $137.1M | $105.7M | ||
| Q4 24 | $145.4M | $108.5M | ||
| Q3 24 | $149.7M | $101.8M | ||
| Q2 24 | $131.7M | $100.1M | ||
| Q1 24 | $138.8M | $87.1M |
净利润SGCZLAB
| Q4 25 | $3.5M | — | ||
| Q3 25 | $2.7M | $-36.0M | ||
| Q2 25 | $1.6M | $-40.7M | ||
| Q1 25 | $-758.0K | $-48.4M | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | $5.4M | $-41.7M | ||
| Q2 24 | $600.0K | $-80.3M | ||
| Q1 24 | $3.9M | $-53.5M |
毛利率SGCZLAB
| Q4 25 | 36.9% | 51.0% | ||
| Q3 25 | 38.3% | 59.5% | ||
| Q2 25 | 38.4% | 60.6% | ||
| Q1 25 | 36.8% | 63.6% | ||
| Q4 24 | 37.1% | 61.5% | ||
| Q3 24 | 40.4% | 64.1% | ||
| Q2 24 | 38.5% | 64.9% | ||
| Q1 24 | 39.8% | 61.4% |
营业利润率SGCZLAB
| Q4 25 | 2.8% | -54.6% | ||
| Q3 25 | 2.3% | -42.3% | ||
| Q2 25 | 1.3% | -50.3% | ||
| Q1 25 | -0.7% | -53.3% | ||
| Q4 24 | 1.7% | -62.6% | ||
| Q3 24 | 4.4% | -66.6% | ||
| Q2 24 | 0.5% | -76.0% | ||
| Q1 24 | 3.3% | -80.7% |
净利率SGCZLAB
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.0% | -31.2% | ||
| Q2 25 | 1.1% | -37.3% | ||
| Q1 25 | -0.6% | -45.8% | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 3.6% | -40.9% | ||
| Q2 24 | 0.5% | -80.2% | ||
| Q1 24 | 2.8% | -61.4% |
每股收益（稀释后）SGCZLAB
| Q4 25 | $0.23 | $-0.05 | ||
| Q3 25 | $0.18 | $-0.03 | ||
| Q2 25 | $0.10 | $-0.04 | ||
| Q1 25 | $-0.05 | $-0.04 | ||
| Q4 24 | $0.12 | $-0.09 | ||
| Q3 24 | $0.33 | $-0.04 | ||
| Q2 24 | $0.04 | $-0.08 | ||
| Q1 24 | $0.24 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.7M | $689.6M |
| 总债务越低越好 | $94.1M | — |
| 股东权益账面价值 | $192.8M | $715.5M |
| 总资产 | $421.8M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.49× | — |
8季度趋势，按日历期对齐
现金及短期投资SGCZLAB
| Q4 25 | $23.7M | $689.6M | ||
| Q3 25 | $16.7M | $717.2M | ||
| Q2 25 | $21.0M | $732.2M | ||
| Q1 25 | $19.8M | $757.3M | ||
| Q4 24 | $18.8M | $779.7M | ||
| Q3 24 | $18.4M | $616.1M | ||
| Q2 24 | $13.4M | $630.0M | ||
| Q1 24 | $22.0M | $650.8M |
总债务SGCZLAB
| Q4 25 | $94.1M | — | ||
| Q3 25 | $100.0M | — | ||
| Q2 25 | $99.3M | — | ||
| Q1 25 | $95.7M | — | ||
| Q4 24 | $86.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益SGCZLAB
| Q4 25 | $192.8M | $715.5M | ||
| Q3 25 | $193.8M | $759.9M | ||
| Q2 25 | $192.1M | $791.7M | ||
| Q1 25 | $194.4M | $810.8M | ||
| Q4 24 | $198.9M | $840.9M | ||
| Q3 24 | $199.5M | $667.7M | ||
| Q2 24 | $200.9M | $704.2M | ||
| Q1 24 | $200.8M | $762.2M |
总资产SGCZLAB
| Q4 25 | $421.8M | $1.2B | ||
| Q3 25 | $415.3M | $1.2B | ||
| Q2 25 | $423.3M | $1.2B | ||
| Q1 25 | $411.0M | $1.2B | ||
| Q4 24 | $415.1M | $1.2B | ||
| Q3 24 | $407.4M | $985.3M | ||
| Q2 24 | $400.3M | $987.4M | ||
| Q1 24 | $408.5M | $988.4M |
负债/权益比SGCZLAB
| Q4 25 | 0.49× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $17.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | 12.2% | -21.0% |
| 资本支出强度资本支出/营收 | 0.4% | 0.5% |
| 现金转化率经营现金流/净利润 | 5.32× | — |
| 过去12个月自由现金流最近4个季度 | $15.8M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流SGCZLAB
| Q4 25 | $18.4M | $-26.0M | ||
| Q3 25 | $-1.7M | $-32.0M | ||
| Q2 25 | $4.9M | $-31.0M | ||
| Q1 25 | $-2.0M | $-61.7M | ||
| Q4 24 | $8.9M | $-55.8M | ||
| Q3 24 | $8.2M | $-26.8M | ||
| Q2 24 | $6.9M | $-42.2M | ||
| Q1 24 | $9.4M | $-90.1M |
自由现金流SGCZLAB
| Q4 25 | $17.9M | $-26.7M | ||
| Q3 25 | $-2.4M | $-35.0M | ||
| Q2 25 | $3.3M | $-33.9M | ||
| Q1 25 | $-3.1M | $-63.2M | ||
| Q4 24 | $7.4M | $-58.4M | ||
| Q3 24 | $7.3M | $-28.2M | ||
| Q2 24 | $5.6M | $-42.9M | ||
| Q1 24 | $8.8M | $-91.1M |
自由现金流率SGCZLAB
| Q4 25 | 12.2% | -21.0% | ||
| Q3 25 | -1.7% | -30.4% | ||
| Q2 25 | 2.3% | -31.1% | ||
| Q1 25 | -2.3% | -59.9% | ||
| Q4 24 | 5.1% | -53.8% | ||
| Q3 24 | 4.9% | -27.7% | ||
| Q2 24 | 4.2% | -42.9% | ||
| Q1 24 | 6.3% | -104.5% |
资本支出强度SGCZLAB
| Q4 25 | 0.4% | 0.5% | ||
| Q3 25 | 0.5% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 0.8% | 1.5% | ||
| Q4 24 | 1.0% | 2.4% | ||
| Q3 24 | 0.6% | 1.3% | ||
| Q2 24 | 1.0% | 0.7% | ||
| Q1 24 | 0.5% | 1.1% |
现金转化率SGCZLAB
| Q4 25 | 5.32× | — | ||
| Q3 25 | -0.61× | — | ||
| Q2 25 | 3.18× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 4.28× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 11.42× | — | ||
| Q1 24 | 2.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SGC
| Branded Products | $96.9M | 66% |
| Healthcare Apparel | $28.8M | 20% |
| Contact Centers | $21.7M | 15% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
